ZA202402153B - Lyophilised formulations of mrna adsorbed onto lipid nano-emulsion particles. - Google Patents
Lyophilised formulations of mrna adsorbed onto lipid nano-emulsion particles.Info
- Publication number
- ZA202402153B ZA202402153B ZA2024/02153A ZA202402153A ZA202402153B ZA 202402153 B ZA202402153 B ZA 202402153B ZA 2024/02153 A ZA2024/02153 A ZA 2024/02153A ZA 202402153 A ZA202402153 A ZA 202402153A ZA 202402153 B ZA202402153 B ZA 202402153B
- Authority
- ZA
- South Africa
- Prior art keywords
- adsorbed onto
- emulsion particles
- lipid nano
- lyophilised formulations
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Plant Pathology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202121038492A IN202121038492A (https=) | 2021-08-25 | 2021-08-25 | |
| PCT/IN2022/050753 WO2023026301A1 (en) | 2021-08-25 | 2022-08-24 | LYOPHILISED FORMULATIONS OF mRNA ADSORBED ONTO LIPID NANO-EMULSION PARTICLES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202402153B true ZA202402153B (en) | 2024-10-30 |
Family
ID=85321644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2024/02153A ZA202402153B (en) | 2021-08-25 | 2024-03-18 | Lyophilised formulations of mrna adsorbed onto lipid nano-emulsion particles. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240350413A1 (https=) |
| EP (1) | EP4392023A4 (https=) |
| JP (1) | JP7821271B2 (https=) |
| KR (1) | KR20240046787A (https=) |
| AU (1) | AU2022335015B2 (https=) |
| CA (1) | CA3229958A1 (https=) |
| CL (1) | CL2024000566A1 (https=) |
| CO (1) | CO2024002142A2 (https=) |
| IN (1) | IN202121038492A (https=) |
| WO (1) | WO2023026301A1 (https=) |
| ZA (1) | ZA202402153B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220156933A (ko) | 2020-03-23 | 2022-11-28 | 에이치디티 바이오 코포레이션 | Rna의 전달을 위한 조성물 및 방법 |
| WO2023048760A1 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Rna vaccines against infectious diseases |
| JP2024535354A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | がん治療組成物およびその使用 |
| EP4404919A4 (en) | 2021-09-22 | 2025-08-20 | Hdt Bio Corp | DRIED NANOPARTICLE COMPOSITIONS |
| CA3232719A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Sars-cov-2 rna vaccine compositions and methods of use |
| WO2024261766A1 (en) * | 2023-06-23 | 2024-12-26 | Gennova Biopharmaceuticals Ltd. | Lyophilised vaccine formulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4026568A1 (en) * | 2015-04-17 | 2022-07-13 | CureVac Real Estate GmbH | Lyophilization of rna |
| US20240350410A1 (en) * | 2021-08-16 | 2024-10-24 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
-
2021
- 2021-08-25 IN IN202121038492A patent/IN202121038492A/en unknown
-
2022
- 2022-08-24 AU AU2022335015A patent/AU2022335015B2/en active Active
- 2022-08-24 EP EP22860802.2A patent/EP4392023A4/en active Pending
- 2022-08-24 CA CA3229958A patent/CA3229958A1/en active Pending
- 2022-08-24 US US18/686,065 patent/US20240350413A1/en active Pending
- 2022-08-24 WO PCT/IN2022/050753 patent/WO2023026301A1/en not_active Ceased
- 2022-08-24 KR KR1020247009783A patent/KR20240046787A/ko active Pending
- 2022-08-24 JP JP2024512095A patent/JP7821271B2/ja active Active
-
2024
- 2024-02-23 CO CONC2024/0002142A patent/CO2024002142A2/es unknown
- 2024-02-23 CL CL2024000566A patent/CL2024000566A1/es unknown
- 2024-03-18 ZA ZA2024/02153A patent/ZA202402153B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4392023A1 (en) | 2024-07-03 |
| IN202121038492A (https=) | 2023-03-03 |
| WO2023026301A1 (en) | 2023-03-02 |
| US20240350413A1 (en) | 2024-10-24 |
| JP2024532292A (ja) | 2024-09-05 |
| EP4392023A4 (en) | 2025-07-09 |
| KR20240046787A (ko) | 2024-04-09 |
| CO2024002142A2 (es) | 2024-04-18 |
| AU2022335015A1 (en) | 2024-03-14 |
| CL2024000566A1 (es) | 2024-09-23 |
| CA3229958A1 (en) | 2023-03-02 |
| AU2022335015B2 (en) | 2025-04-10 |
| JP7821271B2 (ja) | 2026-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202402153B (en) | Lyophilised formulations of mrna adsorbed onto lipid nano-emulsion particles. | |
| GB2589795B (en) | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids | |
| MY199911A (en) | Self-righting systems and related components and methods | |
| ZA202400149B (en) | Rna adsorbed onto lipid nano-emulsion particles and its formulations. | |
| EP3880717A4 (en) | Compositions and methods for delivering crispr/cas effector polypeptides | |
| MX2022007680A (es) | Nanoparticulas lipidicas para administracion de acidos nucleicos. | |
| CO2018011554A2 (es) | Formulaciones de nanopartículas lipídicas para componentes de cas/crispr | |
| EP4696361A3 (en) | Systems and methods for liquid injection | |
| MA42895A (fr) | Cellules modifiées pour thérapie cellulaire adoptive | |
| SA519410101B1 (ar) | Magl مثبطات و faah مزدوجة | |
| CO2021001472A2 (es) | Inhibidores de transglutaminasa 2 (tg2) | |
| EP4574172A3 (en) | Ionizable cationic lipids for lipid nanoparticles | |
| EP4635481A3 (en) | Biodegradable lipids for the delivery of active agents | |
| MX2010009866A (es) | Composiciones de inhibidores de angiogenesis en nanoparticulas. | |
| IL317109A (en) | Lipid nanoparticles for the delivery of nucleic acids and methods of using them | |
| EP3937905A4 (en) | RINSING COMPOSITIONS AND THEIR USES FOR THE ADMINISTRATION OF ACTIVE AGENTS | |
| MX2021002935A (es) | Formulacion de anticuerpos contra csf-1r. | |
| MX2023009082A (es) | Formulacion liposomal para la lubricacion articular. | |
| EP3999117A4 (en) | NANOPARTICLE SYSTEMS FOR TARGETED CRISPR/CAS13 DELIVERY AND METHODS OF USE THEREOF | |
| BR112022009431A2 (pt) | Artigos abrasivos e métodos para formação dos mesmos | |
| MY209656A (en) | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability | |
| EP4003392A4 (en) | PEPTIDES FOR THE TREATMENT OF NON-EXCESSIVE MACULAR DEGENERATION AND OTHER EYE DISEASES | |
| WO2016116760A3 (en) | Inhibitors of the interaction between clec14a and multimerin-2 for inhibition of angiogenesis | |
| MX2021008188A (es) | Compuestos de anandamida. | |
| PH12021551760A1 (en) | Amino acid derivatives for the treatment of inflammatory diseases |